CTOs on the Move

Mccrone Group Inc

www.mccrone.com

 
Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.mccrone.com
  • 850 Pasquinelli Dr
    Westmont, IL USA 60559
  • Phone: 630.887.7100

Executives

Name Title Contact Details

Similar Companies

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.

Collaborating Docs

We help nurse practitioners and physician assistants find amazing collaborative physicians in less than a week.

Harsha Behavioral Center

Harsha Behavioral Center is a freestanding acute psychiatric care hospital serving children, adolescents, adults, and geriatrics in the Wabash Valley, Vigo County area in and around Terre Haute, Indiana. Harsha Center, Paras Harshawat M.D.

Legacy Pharmaceuticals International

Legacy Pharmaceuticals International is a Humacao, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.